ICON CLINICAL RESEARCH SRO

Their core work

ICON Clinical Research SRO is the Czech Republic subsidiary of ICON plc, one of the world's five largest Contract Research Organizations (CROs). Their core business is clinical trial management and operations — they are hired by pharmaceutical and biotech clients to plan, run, and report clinical studies according to GCP and regulatory requirements. In H2020 projects, ICON appeared as a contracted third-party clinical operations partner, not as a primary research institution: they handled the trial execution while the science was led by others. Both of their EU research project involvements center on the same PLX-PAD placenta-derived stromal cell therapy, suggesting they were the designated CRO for that specific drug development program across its Phase IIb and Phase III stages.

What they specialise in

How they've shifted over time

ICON's two H2020 projects represent a single clinical development arc rather than two distinct research directions: PACE (2017–2021, Phase IIb) and HIPGEN (2018–2022, Phase III) both involve the same PLX-PAD therapy, with ICON supporting the program as it advanced toward regulatory approval. The absence of early keywords from PACE and the concentration of all keywords in HIPGEN reflects that the Phase III trial was the more defined, protocol-mature study — not a change in focus but a deepening of the same therapeutic area. With only two overlapping projects on a single platform, it is not possible to identify a broader strategic shift in ICON's H2020 portfolio.

ICON's H2020 footprint tracks the clinical maturation of a single ATMP program from proof-of-concept to pivotal trial, positioning them as an experienced CRO for late-stage Advanced Therapy Medicinal Product development in the EU regulatory environment.

How they like to work

ICON does not lead consortia or drive research agendas — in both H2020 projects they appear exclusively as a contracted third party, a structural role that reflects how CROs typically engage with publicly-funded research: as execution specialists hired by the consortium, not co-investigators. Despite only two projects, they connected with 20 distinct partners across 10 countries, which mirrors the multinational, multi-site nature of Phase II-III clinical trials where each participating hospital or clinic counts as a network node. This means working with ICON means engaging a service provider with defined deliverables, not a scientific collaborator sharing intellectual risk.

Through just two projects, ICON touched 20 distinct consortium partners across 10 countries — an unusually broad network for such a small project count, explained by the multinational clinical site structures required for Phase II-III trials. Their geographic footprint likely spans major EU clinical research hubs, with the Czech entity serving as the Central and Eastern European operational anchor.

What sets them apart

As the Czech arm of a global top-5 CRO, ICON SRO brings enterprise-grade GCP infrastructure, regulatory affairs expertise, and multinational trial coordination to EU research consortia — capabilities rarely available from academic or SME partners. Their specific track record with ATMPs (Advanced Therapy Medicinal Products) is particularly valuable: cell and gene therapy trials carry far higher operational complexity than conventional drug trials, and regulators scrutinize CRO competence closely. For a consortium building a clinical work package around an innovative cell therapy, ICON CZ offers a credible, accredited execution partner with direct experience in exactly this product class.

Highlights from their portfolio

• HIPGEN
  A pivotal Phase III trial — the highest clinical evidence level before market authorization — targeting hip fracture recovery in elderly patients using PLX-PAD cell therapy, representing ICON's most advanced and regulatory-consequential EU research role.
• PACE
  The Phase IIb precursor to HIPGEN, this multicenter study using HLA-unmatched allogeneic placental stromal cells was an early proof-of-concept for an ATMP that ICON then carried through to Phase III, demonstrating continuity across a full late-stage clinical development program.